It is interesting to note that the announcement does not detail the split of funds received. Only $200k has been paid for the 33% equity held in the Ivy Entities. The balance of $1.3m is a co-contribution from Ivy towards unspecified contingent tax liabilities of Ivy that CCA is obliged to settle by virtue of the terms of the Ivy operating agreement. Those liabilities are estimated by Ivy to be between $2.7m and $3.5m gross. So, CCA will have a net payable. There may be some offset against this but CCA has not provided any information in this regard. It is worth noting too that a large quantity of the 117m Ivy tokens "returned" to Ivy are to be held in escrow for 18 months and will not be returned to Ivy in the event of any action being brought "against CCA, Elmoson or the prior Officers of CCA who were alsothe Managers of Ivy, during the 18 month escrow period". An interesting condition to impose.
- Forums
- ASX - By Stock
- CCA
- Ann: Finalisation of Ivy Project divestment
CCA
change financial limited
Add to My Watchlist
2.94%
!
7.0¢

Ann: Finalisation of Ivy Project divestment, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
7.0¢ |
Change
0.002(2.94%) |
Mkt cap ! $48.07M |
Open | High | Low | Value | Volume |
7.0¢ | 7.0¢ | 7.0¢ | $0 | 2 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 250000 | 6.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 9800 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 250000 | 0.068 |
1 | 4000 | 0.067 |
2 | 250000 | 0.065 |
2 | 156451 | 0.062 |
2 | 172426 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 9800 | 2 |
0.072 | 3000 | 1 |
0.073 | 573042 | 1 |
0.074 | 130000 | 2 |
0.075 | 200000 | 1 |
Last trade - 15.06pm 04/07/2025 (20 minute delay) ? |
Featured News
CCA (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online